HOME >> MEDICINE >> NEWS
OHSU scientists test medication to treat involuntary weight loss

s to develop and test a medication that would have the same effect. This medication, and others in its class, have excellent oral absorption, which also enhances their appeal as drug candidates.

In this research, the scientists gave both normal mice and mice with a cachexia-like syndrome Neurocrine's orally-administered medication that blocks the MC4 receptor in the brain. In both cases, the animals' appetites increased and their metabolic rates decreased, ultimately resulting in the resumption of normal growth and accumulation of muscle mass. Researchers now hope to conduct clinical trials where both healthy human patients and those suffering from cachexia receive related oral medications to determine the drug's safety and effectiveness.

"We believe the results obtained in this collaborative study with OHSU will provide an important proof-of-principle for Neurocrine's small molecule MC4 receptor antagonist program in animal models relevant for cachexia," said Alan C Foster, Ph.D., Neurocrine Fellow and head of Neurocrine's neuroscience group. Neurocrine is a San Diego-based company that is developing medications related to weight regulation. "We hope to advance an optimized molecule into the first stages of human clinical testing later this year."

"While a lot of attention is paid to the country's obesity epidemic, researchers at OHSU also investigate the other side of weight regulation which is not as well-publicized -- extreme weight loss," said Roger Cone, Ph.D., director of the Center for the Study of Weight Regulation and Associated Disorders. "Cachexia and disorders like it can have extremely serious consequences on patients. This research not only provides hope for these patients, it is also provides another important piece of the puzzle in regards to the brain's control over weight regulation."

The Center for the Study of Weight Regulation and Associated Disorders is a new research institute at Oregon Health & Science
'"/>

Contact: Jim Newman
newmanj@ohsu.edu
503 494-8231
Oregon Health & Science University
29-Mar-2005


Page: 1 2 3

Related medicine news :

1. Earlier use of prostate cancer vaccines urged by Hopkins scientists
2. Tobacco industry pays scientists to challenge secondhand smokes link to infant death risk
3. Schepens scientists regenerate optic nerve for the first time
4. OHSU scientists develop MRI approach to improve breast cancer detection
5. UCLA neuroscientists pinpoint new function for mirror neurons
6. Jefferson scientists uncover potential trigger of diabetic kidney disease
7. Johns Hopkins scientists receive presidential medals
8. UCLA brain scientists crack mystery of how alcohol causes intoxication
9. Wisconsin scientists grow critical nerve cells
10. Jefferson scientists help explain statins effects in Alzheimers disease
11. Jefferson scientists find zinc may help prevent esophageal, oral cancers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OHSU scientists test medication treat involuntary weight loss

(Date:8/31/2015)... ... August 31, 2015 , ... It’s a lot like coming home. Life-long ... of Geneva. During his first days on the job, he’s run into residents of ... and I like knowing that they’re living in such a wonderful place,” he said. ...
(Date:8/31/2015)... Riviera Beach, FL (PRWEB) , ... August 31, 2015 , ... ... Wilander to their growing list of major sports figures who are finding joint pain ... Slam titles, and former #1 men’s tennis player in the world said, “For the ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... the Talent Management Division , a department devoted to helping organizations identify ... Talent management goes beyond selection, and The Brooks Group believes in offering a ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... networking and relationship-marketing firm, announced today the nominees vying for the 2015 ... U.S. Region. Executives include top-ranking decision makers representing national to global organizations ...
(Date:8/31/2015)... ... August 31, 2015 , ... PartnerTech hosted ... Owners and provided a tour of their North American facility following the S.M.A.R.T ... international companies expanding business in the U.S. , The PartnerTech Inc. North ...
Breaking Medicine News(10 mins):Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 4Health News:PartnerTech Supports Economic Growth as Host 2
(Date:8/31/2015)... , Aug. 31, 2015  QT Vascular Ltd., together ... and together with its subsidiaries, the "Group"), a ... distribution of advanced therapeutic solutions for the minimally ... final results of the below-the-knee ("BTK") cohort of ... which were presented on August 15, 2015 at ...
(Date:8/31/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company ... for the treatment of diseases of the central nervous ... IND submission has passed review by the US Food ... Phase 1 clinical trial in patients with metastatic colon ... to 31 December 2015. Bionomics, CEO & ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
Breaking Medicine Technology:Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
Cached News: